Sugi Predict

Sugi Predict / Targets / ABL1

ABL1

Tyrosine-protein kinase ABL1 · P00519 · ABL1 on Sugi Atlas →

448,948 patent compounds predicted against ABL1, 286,771 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1365 SCHEMBL1365 1.00 20/20
Imatinib Imatinib (SCHEMBL3827) 1.00 20/20
Imatinib Imatinib (SCHEMBL8217) 1.00 20/20
SCHEMBL9469 SCHEMBL9469 0.76 20/20
SCHEMBL1442 SCHEMBL1442 1.00 19/20
SCHEMBL9485 SCHEMBL9485 1.00 19/20
SCHEMBL1430 SCHEMBL1430 1.00 18/20
SCHEMBL1762 SCHEMBL1762 1.00 18/20
SCHEMBL9338 SCHEMBL9338 1.00 18/20
SCHEMBL9565 SCHEMBL9565 1.00 18/20
SCHEMBL9763 SCHEMBL9763 1.00 18/20
SCHEMBL9838 SCHEMBL9838 1.00 18/20
SCHEMBL10208 SCHEMBL10208 0.82 18/20
SCHEMBL1255 SCHEMBL1255 0.80 18/20
SCHEMBL1465 SCHEMBL1465 1.00 17/20
SCHEMBL1522 SCHEMBL1522 1.00 17/20
SCHEMBL9642 SCHEMBL9642 1.00 17/20
SCHEMBL10811 SCHEMBL10811 0.57 17/20
Nilotinib Nilotinib (SCHEMBL7901) 1.00 16/20
SCHEMBL9197 SCHEMBL9197 1.00 16/20

Clinical trials — most relevant to ABL1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study in Adult Ph-positive ALL PHASE2UNKNOWN
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation PHASE2COMPLETED
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia PHASE2UNKNOWN
Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy PHASE2ACTIVE_NOT_RECRUITING
Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage PHASE2COMPLETED
Treatment Modification Based on Early Assessment of CML Patients PHASE2UNKNOWN
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE) PHASE2NOT_YET_RECRUITING
Bosutinib in Elderly Chronic Myeloid Leukemia PHASE2COMPLETED
STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic Leukemia PHASE2COMPLETED
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia PHASE2COMPLETED
De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia PHASE2COMPLETED
Venetoclax After TKI to Target Persisting Stem Cells in CML PHASE2ACTIVE_NOT_RECRUITING
Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase PHASE2COMPLETED
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) PHASE1NOT_YET_RECRUITING
Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL PHASE1COMPLETED
Effect of 2nd Gen TKI in CML nanCOMPLETED
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia nanRECRUITING
The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia nanUNKNOWN
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib nanUNKNOWN
TIGIT in Patients With Chronic Myeloid Leukemia nanUNKNOWN
CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey nanCOMPLETED
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm nanUNKNOWN
Pre-existing Kinase Domain Mutations in Ph-positive Leukemias nanUNKNOWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING
Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia nanCOMPLETED
Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes nanUNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ABL1 binder may also engage these)

ProteinNameSimilarity
P00520 — 1.000 P00520 →
Q8BGT6 — 0.997 Q8BGT6 →
Q5R8Z4 — 0.995 Q5R8Z4 →
Q4JIM5 — 0.995 Q4JIM5 →
Q9H329 — 0.994 Q9H329 →
Q9HCH5 — 0.993 Q9HCH5 →
E9Q9W7 — 0.993 E9Q9W7 →
Q8VDU5 — 0.993 Q8VDU5 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.992 landscape →
Q8BWQ5 — 0.992 Q8BWQ5 →
O94885 — 0.992 O94885 →
ABL2 Tyrosine-protein kinase ABL2 0.992 landscape →
Q9H5P4 — 0.992 Q9H5P4 →
Q9ERE6 — 0.992 Q9ERE6 →
Q3ULB5 — 0.991 Q3ULB5 →
Q5RBR0 — 0.991 Q5RBR0 →
B1AQJ2 — 0.991 B1AQJ2 →
A6QP06 — 0.991 A6QP06 →
P47709 — 0.991 P47709 →
Q3UIZ8 — 0.991 Q3UIZ8 →
Q5VZ18 — 0.991 Q5VZ18 →
Q8BSD5 — 0.991 Q8BSD5 →
Q6DN90 — 0.990 Q6DN90 →
Q91X43 — 0.990 Q91X43 →
O54967 — 0.990 O54967 →
Q5RAK6 — 0.990 Q5RAK6 →
Q9C0D6 — 0.990 Q9C0D6 →
KDM2B Lysine-specific demethylase 2B 0.990 landscape →
Q8BZT2 — 0.990 Q8BZT2 →
Q76LL6 — 0.990 Q76LL6 →